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The adaptor molecule stimulator of IFN genes (STING) is central to
production of type I IFNs in response to infection with DNA viruses
and to presence of host DNA in the cytosol. Excessive release of
type I IFNs through STING-dependent mechanisms has emerged as
a central driver of several interferonopathies, including systemic
lupus erythematosus (SLE), Aicardi–Goutières syndrome (AGS),
and stimulator of IFN genes-associated vasculopathy with onset
in infancy (SAVI). The involvement of STING in these diseases points
to an unmet need for the development of agents that inhibit STING
signaling. Here, we report that endogenously formed nitro-fatty
acids can covalently modify STING by nitro-alkylation. These nitro-
alkylations inhibit STING palmitoylation, STING signaling, and sub-
sequently, the release of type I IFN in both human and murine cells.
Furthermore, treatment with nitro-fatty acids was sufficient to inhibit
production of type I IFN in fibroblasts derived from SAVI patients with
a gain-of-function mutation in STING. In conclusion, we have iden-
tified nitro-fatty acids as endogenously formed inhibitors of STING
signaling and propose for these lipids to be considered in the
treatment of STING-dependent inflammatory diseases.
nitro-fatty acids | STING | palmitoylation | IFN | SAVI
The adaptor molecule stimulator of IFN genes (STING) iscentral to production of type I IFN in response to cytosolic
DNA (1–3). Accumulating evidence now points to STING as a
source of severe pathology in human disease. Most recently, gain-of-
function mutations in the gene encoding STING (TMEM173) have
been shown to drive a systemic and debilitating inflammatory con-
dition known as stimulator of IFN genes-associated vasculopathy
with onset in infancy (SAVI) (4). Other inflammatory diseases, such
as Aicardi–Goutières syndrome, familial chilblain lupus, and retinal
vasculopathy with cerebral leukodystrophy, also seem to depend on
induction of type I IFN via STING activation (5–9). The involve-
ment of STING in human disease highlights the unmet demand for
treatments that target the ability of STING to induce release of
proinflammatory cytokines, including type I IFNs.
STING is a transmembrane adaptor protein that signals down-
stream of the DNA sensor cGMP-AMP synthase (cGAS). On
binding of dsDNA, cGAS catalyzes the formation of the cGMP-AMP
(cGAMP), which binds to and activates STING (10–12). Binding of
cGAMP to STING leads to recruitment and phosphorylation of
the signaling molecule TANK-binding kinase 1 (TBK1) (13). Next,
TBK1 mediates phosphorylation of the transcription factor IFN
regulatory factor 3 (IRF3), which translocates to the nucleus as
homodimers to initiate transcription of several cytokine genes,
including type I IFNs (IFN-α/β) (13). Structurally, human STING
is composed of a membrane-associated N-terminal region (amino
acids 1–137), which includes four predicted transmembrane helices
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and a relatively large cytosolic C-terminal domain (amino acids
138–379). The structure of the cytosolic domain has been solved by
X-ray crystallography and has been identified as the site of cGAMP
binding and TBK1 and IRF3 phosphorylation (14–17). By contrast,
it is largely unknown how the N-terminal region and its four
predicted transmembrane regions contribute to STING function.
However, a recent study has identified N-terminal cysteine residues
at positions 88 and 91 as targets of palmitoylation in response to
stimulation with cytosolic dsDNA. Palmitoylation at Cys88/91
was important for STING-dependent phosphorylation of TBK1
in the trans-Golgi network (TGN) and thus, central to STING-
dependent induction of type I IFNs (18). It is currently unknown
if palmitoylation at these cysteine residues can be targeted to
inhibit STING signaling.
Recently, nitro-fatty acids (NO2-FAs) have emerged as a group
of bioactive lipids with antiinflammatory properties (19). At this
stage, only a limited number of NO2-FAs have been identified, and
their importance in immune regulation during infection is poorly
understood. Endogenous formation of NO2-FAs is the result of
nitrogen dioxide (•NO2) addition preferentially to unsaturated
fatty acids, such as conjugated linoleic acid (cLA) and oleic acid
(OA), to form nitro-conjugated linoleic acid (NO2-cLA) and nitro-
oleic acid (NO2-OA), respectively (20). During inflammation, for-
mation of •NO2 depends on the presence of inducible nitric oxide
synthase (iNOS)-derived •NO, its autooxidation, or its reaction with
oxygen species, including the NADPH oxidase (NOX)-derived su-
peroxide anion O2
−• (21). The •NO2 reacts with lipid species to form
NO2-FAs (22) (Fig. 1A).
Formed NO2-FAs have the ability to modify target proteins
posttranslationally (S-nitro-alkylation) through Michael addition
reactions. The thiol group on cysteine residues is a preferred
target, and NO2-FAs have been shown to modify the proteins,
like Kelch-like ECH-associated protein 1, a repressor of the
transcription factor Nuclear factor (erythroid-derived 2)-like 2
(Nrf2) (23), the signaling protein Peroxisome Proliferator-
activated Receptor-γ (PPARγ) (24), and NF-κB (19). In these
selected cases, nitro-alkylation leads to modulation of downstream
signaling events, resulting in changes in metabolic, inflammatory,
and antioxidative pathways.
Here, we show that NO2-FAs can be formed in response to
viral infection. Furthermore, we show that NO2-FAs can inhibit
STING signaling and the release of type I IFNs in response to
stimulation with the STING agonists, dsDNA and cGAMP, in
addition to infection with the DNA virus HSV-2. Mechanistically,
Fig. 1. NO2-FAs are formed after HSV-2 infection. (A) Schematic of the formation of NO2-FAs induced by iNOS/NOX production of NO species during virus infection. (B)
Plasma and (C) vaginal lavages after inoculationwith cLA (1mM) in the vaginal lumen fromWT andNos2−/−C57BL/6mice infected intravaginally with HSV-2 (6.7 ×104 pfu
per mouse) were harvested at day 2 postinfection and analyzed for NO2-cLA formation by mass spectrometry. One representative experiment of two independent
experiments is shown. Data are represented as box/whiskers with (B) n = 7 mice per group and (C) n = 8 (untreated) or 12 (HSV-2 infected) mice per group. ns, Not
significant. *P < 0.05 (unpaired Mann–Whitney U test). (D) RAW264.7 (WT) cells, (E) RAW264.7 control cells (empty vector) or RAW264.7 cells with CRISPR/Cas9-
mediated deletion of Nos2 expression, and (F) BMMs from WT or Nos2−/− mice were stimulated with combinations of IFN-γ (10 ng/mL), LPS (1 μg/mL), and HSV-2
(MOI 0.5) in the presence of cLA (100 μM). After 20 h of stimulation, supernatants were analyzed for NO2-cLA formation by mass spectrometry. (D–F) Data
represent three biological replicates in one experiment and are displayed as mean ± SEM. (G) Representative chromatogram showing coelution between samples
(LPS + IFN-γ, HSV-2 + IFN-γ, and HSV-2) and standard, confirming the presence of NO2-cLA.
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NO2-FAs directly modified STING through nitro-alkylation at the
two adjacent cysteines at positions 88 and 91 (Cys88/91) and at an
N-terminal histidine (His16), leading to a deregulation of STING
palmitoylation and inhibition of STING signaling. Additionally,
NO2-FA treatment of immortalized fibroblasts from SAVI patients
led to decreased STING-dependent type I IFN responses.
In conclusion, we show that endogenously formed NO2-FAs
are potent inhibitors of STING signaling and suggest that NO2-
FAs could be considered as a lipid-based treatment for STING-
dependent inflammatory diseases.
Results
NO2-FAs Are Formed in Response to Infection with Virus. As HSV
infections are associated with release of high levels of reactive
nitrogen species (25, 26), we tested if NO2-FAs were formed in a
model of vaginal HSV-2 infection, which induces a strong ex-
pression of iNOS (27). Expression of iNOS was most profoundly
induced in leukocytes (CD45+ cells) at day 2 postinfection with
HSV-2 (SI Appendix, Fig. S1); thus, plasma and vaginal lavages
were collected at this time point. We found formation of the
NO2-FA species NO2-cLA in response to HSV-2 infection in
plasma (Fig. 1B) and in vaginal lavages after cLA inoculation
(Fig. 1C). Despite biological variation between individual mice,
the observed NO2-cLA formation was significantly higher during
HSV-2 infection in WT mice. Consequently, we report potent
endogenous NO2-FA formation after infection. Consistent with
the concept of NO2-FA generation being dependent on iNOS, a
robust increase in NO2-cLA formation was found in WT mice
but not in mice deficient in the NO-forming enzyme iNOS
(nos2−/−) (Fig. 1 B and C). However, we did observe elevated
basal levels of NO2-cLA in plasma from nos2
−/− mice, pointing to a
compensatory but HSV-2–insensitive release of NO species by other
enzymes (Fig. 1B). Formation of NO2-cLA was also observed in vitro
when infecting WT RAW264.7 cells with HSV-2 in the presence of
the parent nonnitrated unsaturated lipid (cLA) serving as a template
for NO2-FA formation (Fig. 1D). Similarly, RAW264.7 cells (empty
vector) (Fig. 1E) or bone marrow-derived macrophages (BMMs)
from WT mice (Fig. 1F) likewise formed NO2-cLA in response
HSV-2 infection. In contrast, no NO2-cLA formation was ob-
served in iNOS-deficient RAW264.7 cells or BMMs (Fig. 1 F and
G). Notably, the in vitro release of NO2-cLA required the presence
of IFN-γ (Fig. 1 E and F) beside iNOS-dependent •NO formation
(SI Appendix, Fig. S2). Remarkably, the combination of LPS and
IFN-γ induced the highest in vitro release of both •NO-derived
species (SI Appendix, Fig. S2) and NO2-cLA formation (Fig. 1 E–
G). Together, these results suggest that NO2-cLA formation is oc-
curring naturally in response to in vivo HSV-2 infection and after in
vitro stimulation with LPS/IFN-γ and HSV-2/IFN-γ.
NO2-FAs Inhibit Release of Type I IFN. Since NO2-FAs have previously
been reported to possess antiinflammatory properties (19), we next
sought to test if various NO2-FA species (NO2-cLA, 9-NO2-OA,
and 10-NO2-OA) could affect the release of type I IFNs to HSV-
2 and HSV-2–derived stimuli as cytosolic dsDNA and cGAMP.
We found that pretreatment with NO2-FA led to highly reduced
induction of type I IFNs in response to HSV-2 in both THP-1 cells
(Fig. 2A) and BMMs (Fig. 2C). Comparable reduction was ob-
served after NO2-FA treatment before stimulation with dsDNA in
THP-1 cells (Fig. 2B) and in BMMs (Fig. 2D). Treatment with
NO2-FA species after HSV-2 infection also led to reduced release
for the IFN-induced cytokine CXCL10 (SI Appendix, Fig. S3). In
addition, release of the proinflammatory cytokine IL-6 was like-
wise decreased on NO2-FA treatment in various cell types (SI
Appendix, Fig. S4). NO2-FA treatment also reduced the release of
other proinflammatory cytokines induced via Toll-like receptor-
dependent and RIG-I–like receptor-dependent pathways (SI Appen-
dix, Fig. S5). By contrast, type I IFN release was largely unaffected
after treatment with the nonnitrated parent lipids linoleic acid (LA)
and oleic acid (OA). The effect of NO2-FAs on cytokine production
was independent of Nrf2 activation (SI Appendix, Fig. S6) and
PPARγ pathway (SI Appendix, Fig. S7), as the NO2-FAs retained
their inhibitory effect in various Nrf2-deficient cells and in the pres-
ence of two different PPARγ inhibitors, respectively. Induction of
type I IFNs by infection with DNA viruses, such as HSV-2, and by
stimulation with dsDNA is highly dependent on the cGAS-STING
pathway (10, 11, 28). We, therefore, hypothesized that NO2-FAs
could possibly inhibit signaling through this pathway. By immuno-
blotting, we showed that treatment with NO2-FA species led to re-
duced phosphorylation of STING, TBK1, and IRF3 as well as to
reduced formation of STING and IRF3 dimers after stimulation
with either cGAMP (Fig. 2 E and F and SI Appendix, Fig. S8) or
dsDNA (Fig. 2 E and G). Collectively, these results suggest that
NO2-FAs are able to reduce type I IFN levels prominently by
affecting the cGAS-STING signaling pathway.
NO2-FAs Bind STING and Block STING Palmitoylation. Interestingly,
we noticed a subtle but consistent mobility shift of STINGmonomers
under nonreducing conditions (Fig. 2 E–G). This observation could
implicate STING as an NO2-FA target. To investigate this further,
cells were treated with biotinylated forms of one NO2-FA species,
10-NO2-OA, and subsequently subjected to immunoprecipitation.
Excitingly, biotinylated 10-NO2-OA readily precipitated STING,
indicating a possible direct modification of STING (Fig. 3 A and B).
Encouraged by these results, human STING-transfected HEK293T
cells were treated with 10-NO2-OA. The precipitated and eluted
STING protein was analyzed for NO2-OA modifications by mass
spectrometry. By this method, three sites of STING nitro-alkylation
were identified: two adjacent cysteine residues at positions 88 and
91 in addition to a histidine residue at position 16 (Fig. 3 C and D).
Common for all three sites is their location in close proximity to
the predicted transmembrane helices of STING. Other than NO2-
OA, we observed NO-OA and NH2-OA as additional modifica-
tions at cysteine residues due to reduction and laser desorption
ionization, and we found one of the peptides partially and fully
reduced and the other partially and nonreduced. None of these
modified peptides were observed in the untreated sample (Fig.
3C). This observation is supported by experiments conducted with
synthetic peptides. As previously described, no such reductions oc-
curred at histidine residues. Additionally, we investigated the
previously described modification of 200 Da (29), which confirmed
our findings (SI Appendix, Figs. S10 and S11).
In resting state, STING resides in the endoplasmic reticulum
(ER) membrane, but binding to cGAMP initiates its translocation
to Golgi membrane (30). Palmitoylation of STING at Cys88/
91 recently has been shown to be essential for STING clustering
in the TGN and for the downstream STING signaling (18). We,
therefore, speculated if the underlying mechanism for NO2-FA–
mediated inhibition of STING signaling could occur by preventing
STING palmitoylation. For detection of palmitoylation, STING-
KO mouse embryonic fibroblasts (MEF) expressing STING-EGFP
were cultured in the presence of radio-labeled palmitate (3H-palmitate)
before stimulation with the mouse STING agonist DMXAA. Us-
ing GFP-specific antibodies, we precipitated STING and subse-
quently determined palmitoylation by measuring 3H-palmitate
using an autoradiograph. As previously reported (18), treatment
with DMXAA led to an increase in incorporation of 3H into
STING (18). In contrast, pretreatment with 10-NO2-OA, but not
with OA, considerably inhibited this process (Fig. 3E). These re-
sults suggest that NO2-FA–modified STING was unable to be
palmitoylated after DMXAA stimulation. Since the palmitoylation
of Cys88 and Cys91 of STING is stimulation dependent and likely
occurs in the Golgi (18), Cys88 and Cys91 may be in the reduced
form when STING is in the ER. We propose that treatment of
cells with NO2-FA before stimulation modifies Cys88 and Cys91 of
STING through nitro-alkylation in the ER, preventing the normal
palmitoylation process that occurs on these Cys residues at the
E7770 | www.pnas.org/cgi/doi/10.1073/pnas.1806239115 Hansen et al.
Golgi. Palmitoylation of STING is important for STING clustering
at the TGN and for phosphorylation of TBK1 at this location (18).
For detailed investigation, we used STING-KO MEFs expressing
STING-EGFP and stimulated with DMXAA. Costaining for pTBK1
and for TGN in the cells expressing STING-EGFP allowed us to test
whether 10-NO2-OA affected STING translocation to the
TGN and/or phosphorylation of TBK1 by confocal microscopy. As
expected, DMXAA stimulation induced translocation of STING to
the perinuclear compartments, and STING colocalized with a TGN
protein TGN38 (Fig. 3F, vehicle). pTBK1 signal showed up and
partly colocalized with STING. OnNO2-FA treatment, in ∼30% of
the cells, the perinuclear translocation of STING was unaffected,
whereas this was markedly reduced in the remaining ∼70% of cells
(Fig. 3F, 10-NO2-OA). Strikingly, phosphorylation of TBK1 was
inhibited regardless of whether STING translocated to the TGN. OA
treatment, as a vehicle treatment, did not affect the perinuclear
translocation of STING and the emergence of phosphorylated TBK1
(Fig. 3F, OA). In summary, NO2-FAs directly modify and nitro-
alkylate STING at Cys88 and Cys91, resulting in inhibited palmi-
toylation and leading to the suppression of phosphorylation of TBK1.
NO2-FAs Inhibit Release of Type I IFN in SAVI-Derived Fibroblasts.Gain-
of-function mutations in the gene encoding STING (TMEM173)
have been shown to drive pathology through excessive release of
type I IFNs in SAVI (4). Since NO2-FAs have been reported to be a
well-tolerated treatment in humans (clinicaltrials.gov: NCT02460146
and NCT02313064), we wanted to determine if NO2-FAs could
decrease type I IFN responses in three SAVI patient-derived fi-
broblast cell lines, all bearing the N154S mutation. Indeed, we
observed that release of type I IFN in response to stimulation with
dsDNA was greatly inhibited in all three patients on treatment with
NO2-FA species (Fig. 4 A–C). In line, the expression of IFN-β as well
as the expression of the two IFN-stimulated genes (ISGs), IFIT1 and
ISG15, were likewise suppressed with NO2-FA treatment (SI Ap-
pendix, Fig. S9). Furthermore, pTBK1, which was highly induced in
the SAVI fibroblasts in response to cGAMP stimulation, was almost
completely abolished by NO2-FA treatment (Fig. 4D). As basal
IFN-β production in fibroblasts was below the detection limit (Fig.
4 A–C), we used expression plasmids harboring gain-of-function
STING mutants previously reported to cause SAVI (V174L, N154S,
and V155M) to further test the treatment potential of NO2-FAs.
Indeed, NO2-FA treatment could dampen the STING-dependent
release of type IFN in a ligand-independent manner in this setup.
In summary, these results imply the therapeutic potential of NO2-
FAs by dampening type I IFN levels in SAVI patient fibroblasts.
Fig. 2. NO2-FAs suppress STING signaling and release of type I IFN. (A and B) THP-1 cells and (C and D) BMMs (WT mice) were treated with indicated NO2-FAs
(5–10 μM) or OA/LA (10 μM) 15 min before stimulation with dsDNA (4 μg/mL) or infection with HSV-2 (MOI 1) or left untreated (Ut). After 20 h, supernatants
were harvested and analyzed for type I IFN. Data represent one of two independent experiments and are presented as mean ± SEM. (E–G) THP-1 cells were
treated with NO2-FAs (10 μM) or OA/LA (10 μM) 15 min before stimulation with cGAMP (4 μg/mL) or dsDNA (4 μg/mL) using Lipofectamine2000 (Lipo). After
3 h, lysates were separated by SDS/PAGE, and indicated proteins were detected by Western blotting using specific antibodies. STING and IRF3 dimers were
detected using nondenaturing and nonreducing conditions. Vinculin was used as loading control.
Hansen et al. PNAS | vol. 115 | no. 33 | E7771
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
Fig. 3. NO2-FAs directly modify STING to inhibit palmitoylation. (A) THP-1 cells with endogenous STING and (B) HEK293T cells transfected with expression
plasmid for human STING plasmid (Flag tagged) were treated with biotinylated 10-NO2-OA (10 μM) or biotinylated OA (10 μM). After 1.5-h incubation, lysates
were precipitated using mixed magnetic Streptavidin beads. Eluates and input samples were separated by SDS/PAGE, and STING (α-Flag) was detected by
Western blotting. Blots represent representative results from two independent experiments. (C) HEK293T cells transfected with an expression plasmid for
human STING were treated with 10-NO2-OA (10 μM). After 1.5 h, STING was precipitated using STING-specific antibody and analyzed for nitro-alkylation by
mass spectrometry. Graphics display (Left) an example spectrum of STING digest: Upper Left in black shows NO2-OA–treated STING, and Lower Left in red
shows untreated STING as a comparison. r.int (%), relative intensity in %. (Upper Right) List of matched peptides. (Lower Right) STING amino acid sequence
with peptides containing nitro-alkylation marked in yellow. Data are displayed from a single experiment. (D) Graphic illustration of the positions of nitro-
alkylated STING residues. (E) Immortalized STING-KO MEFs expressing GFP-tagged STING were treated with 10-NO2-OA (10 μM), OA (10 μM), 2-
bromopalmitate, 2-BP (50 μM), or vehicle control for 1 h. Cells were washed and incubated with radio-labeled palmitate (3H-palmitate) for 1 h before
stimulation with DMXAA (25 mg/mL) or with vehicle control for an additional 1 h. Cells were lysed, and STING was precipitated (IP) using GFP-specific an-
tibodies. Eluate and input were separated by SDS/PAGE and analyzed for contents of radio-labeled palmitate by autoradiography. STING was detected by
immunoblotting, and α-tubulin was used as a loading control. Data displayed are from one of three independent experiments with same result. (F) Immor-
talized STING-KO MEFs expressing GFP-tagged STING were treated with 10-NO2-OA (10 μM), OA (10 μM), or vehicle control as indicated before stimulation with
DMXAA (25 mg/mL) or was left untreated (Ut) for 1 h. Cells that already express STING-GFP (green in merged panels) were fixed and stained for the TGN marker
TGN38 (purple in merged panels) or pTBK1 (purple in merged panels), and the nuclei were stained with DAPI (blue in merged panels) and analyzed by confocal
microscopy. The first three columns represent single stains of EGFP-STING, TGN38, and pTBK1, respectively. The last two columns represent merged pictures of
EGFP-STING together with TGN38 and EGFP-STING together with pTBK1, respectively. Insets illustrate close-ups. Data represent two independent experiments.
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Discussion
Gain-of-function mutations in STING can lead to a neonatal-
onset systemic inflammatory condition characterized by severe
cutaneous vasculopathy with extensive tissue loss and interstitial
lung disease (SAVI) (4). Treatment options for SAVI patients or
for patients with other STING-dependent inflammatory diseases
are very limited. This is partly due to the absence of therapies that
directly target STING signaling. This report identifies naturally
occurring NO2-FAs as potent inhibitors of STING signaling in
human cells, including fibroblasts from SAVI patients. Thus, our
data suggest that NO2-FAs could be considered for trials aimed at
treating patients with STING-dependent interferonopathies. This
is further encouraged by the fact that NO2-FAs are currently
used in phase II trials for focal segmental glomerulosclerosis and
pulmonary arterial hypertension and are here reported to be
well-tolerated by the patients (clinicaltrials.gov: NCT02460146
and NCT02313064).
Our discovery that endogenous concentrations of NO2-FAs
are increased in response to virus-induced inflammation in mice
together with the previous detection of NO2-FA species and
their adducts in human plasma and urine indicate that NO2-FAs
act as natural antiinflammatory mediators (31, 32). Testing this
hypothesis is challenged by the difficulty to specifically eliminate
NO2-FAs from humans and even from mice. Antiinflammatory
effects of the parent nonnitrated unsaturated lipids are widely
reported (33). If part of these antiinflammatory effects is owing
to the conversion into NO2-FAs remains unknown. Notably, the
parent nonnitrated unsaturated lipids have been documented to
activate the PPARγ pathway (34)—also a known NO2-FA target
(24). The idea that highly inflammatory •NO-derived radicals,
produced during inflammation, react with polyunsaturated lipids
to form bioreactive antiinflammatory compounds is an attractive
model for a built-in mechanism to counteract excessive inflam-
mation. This hypothesis is supported by our demonstration that
NO2-FAs are formed in response to HSV-2 infection and in line
with reported detection of NO2-FAs formation in the perito-
neum of mice after LPS injection (21, 35). Future research may
focus on the importance of endogenous formation of NO2-FAs
to control inflammatory conditions in the context of either in-
fection or noninfectious inflammatory disease.
Great advances have been made in understanding the struc-
tural basis for STING signaling in response to cytosolic dsDNA.
Our data expand on this knowledge by identifying palmitoylation
of STING (18) as a modification that can be targeted to inhibit
STING signaling. This finding has considerable medical potential,
as NO2-FAs might either be used directly as antiinflammatory drugs
or be used as a tool for designing highly efficient drugs that specifi-
cally target STING. In brief, our study opens up for embracing the
functionality of the transmembrane helices of STING as targetable in
future attempts to design antiinflammatory drugs.
Fig. 4. NO2-FAs inhibit release of type I IFN from SAVI fibroblasts. (A–C) Immortalized fibroblasts derived from three different SAVI patients were treated
with indicated NO2-FAs (5–10 μM) or OA/LA (10 μM) 15 min before stimulation with dsDNA (4 μg/mL). After 20 h, supernatants were harvested and analyzed
for type I IFN. Data represent three biological replicates in one experiment of each donor and are displayed as mean ± SEM. (D) Immortalized fibroblasts from
one SAVI patient (Pt #1) were treated with indicated NO2-FAs (10 μM) or OA (10 μM) 15 min before stimulation with cGAMP (4 μg/mL). After 3 h, lysates were
separated by SDS/PAGE, and indicated proteins were detected by Western blotting using specific antibodies. Vinculin was used as loading control. Data
represent one experiment with one donor. (E) HEK293T cells were transfected with expression plasmids for WT STING, for three known gain-of-function
STING mutations (V175L, N154S, V155M), or for no plasmid (−). Cells were treated with indicated 10-NO2-OA (2.5–10 μM). Induction of IFN was assessed using
the ISRE luciferase assay. Data are representative of two independent experiments and are displayed as means ± SEM. (F) Graphical abstract depicting how
nitro-alkylation affects STING function. Modified from ref. 18.
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In conclusion, we have discovered that endogenously formed
NO2-FAs can target STING signaling and reduce release of type
I IFNs in both murine and human cells—including fibroblasts from
patients with the STING-dependent interferonopathy SAVI. We,
therefore, suggest that these lipids can be considered in the treat-
ment of STING-dependent inflammatory diseases.
Materials and Methods
Animals. Animals received proper care in agreement with animal protocols
approved by Animal Welfare Bodies at Health, Aarhus University, and we
performed vaginal HSV-2 infection with ethical permission from the An-
imal Experiments Inspectorate, Danish Veterinary and Food Administra-
tion. Full details can be found in SI Appendix, SI Materials and Methods.
Cell Lines and Cell Culture. Full details can be found in SI Appendix, SI Ma-
terials and Methods.
Viruses and Reagents. Full details can be found in SI Appendix, SI Materials
and Methods.
Vaginal HSV-2 Infection. Full details can be found in SI Appendix, SI Material
and Methods.
Analytical Determination of NO2-FAs Levels. Full details can be found in SI
Appendix, SI Materials and Methods.
Cell Stimulation Setups. For in vitro HSV-2 stimulation, multiplicity of infection
(MOI) at 0.5 or 1 was used.
For transfection setups, 4 μg/mL dsDNA (HSV-60; InvivoGen) and 4 μL/mL
Lipofectamine2000 (Invitrogen) were used according to the manufacturer’s
instructions. Furthermore, cGAMP (Invitrogen) was used at a concentration
of 4 μg/mL together 4 μL/mL Lipofectamine2000. Stimulation with cGAMP
was performed using 4 μg/mL delivered to cells using Lipofectacmine2000
(Invitrogen).
Functional Type I IFN Assays. Murine IFN-α/β bioactivity was measured by an
L929 cell-based bioassay as previously described (36). Human type I IFN bio-
activity was quantified using the reporter cell line HEK-Blue IFN-α/β (InvivoGen)
according to the manufacturer’s instructions. SEAP levels were assessed by
measuring OD at 620 nm on a microplate reader (ELx808; BioTEK).
Immunoprecipitation. Cells were lysed in Pierce RIPA lysing buffer (Thermo-
Fisher Scientific) supplemented with 1× complete protease mixture inhibitor
(Roche) and 5 IU mL−1 benzonase (Sigma). Lysate was collected and in-
cubated with Pierce Streptavidin magnetic beads (ThermoFisher Scientific)
for pulldown experiments of biotinylated NO2-FA. Samples were washed
once in PBS supplemented with 0.05% Tween-20, once with lysis buffer, and
four times in 1 M KCl. Samples were eluted in 1× XT Sample Buffer (BioRad)
and 1× XT reducing agent (BioRad) and further processed as described in
Immunoblotting. Dynabeads Protein G (Invitrogen) was used for elution of
STING for mass spectrometry analysis.
Detection of Nitro-Alkylation by Mass Spectrometry. Full details can be found
in SI Appendix, SI Materials and Methods.
Metabolic Labeling with [3H]-Palmitate. Full details can be found in SI Ap-
pendix, SI Materials and Methods.
Immunocytochemistry and Confocal Microscopy. They were previously de-
scribed in ref. 18.
Luciferase Assay. For ARE-Luciferase assays, experiments were performed as
previously described using the calcium phosphate transfection method. After
24 h of transfection and stimulation, luciferase activity was measured with a
dual-luciferase reporter assay and a GloMax 20/20 luminometer as previously
reported (37).
Immunoblotting. Full details can be found in SI Appendix, SI Material and
Methods.
Primary Fibroblast Cell Lines Derived from SAVI Patients’ Superficial Skin
Biopsies. Patients with genetically confirmed SAVI were enrolled into the
protocol (clinicaltrials.gov: NCT02974595) at the NIH between 2008 and 2015.
The protocol was approved by the National Institute of Allergy and In-
fectious Diseases IRB at the NIH. Written informed consent was obtained
from all participating patients or their legal guardians (R.G.-M.). Superficial
research biopsies were obtained, and primary fibroblast cell lines were
generated (4).
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